Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13-12.3

D. S. Verbeek, B. P. van de Warrenburg, P. Wesseling, P. L. Pearson, H. P. Kremer and R. J. Sinke

Departments of Neurology and Pathology, University Medical Center, Nijmegen, and Department of Biomedical Genetics, University Medical Center, Utrecht, the Netherlands

Correspondence to: Dineke Verbeek, Department of Biomedical Genetics, Stratenum 2.112, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG, the Netherlands
E-mail: D.S.Verbeek@med.uu.nl

Summary
We report upon a Dutch autosomal dominant cerebellar ataxia (ADCA) family, clinically characterized by a late-onset (>40 years), slowly progressive, isolated spinocerebellar ataxia (SCA). Neuropathological examination in one affected subject showed neuronal loss in the Purkinje cell layer, dentate nuclei and inferior olives, thinning of cerebellopontine tracts, demyelination of posterior and lateral columns in the spinal cord, as well as ubiquitin-positive intranuclear inclusions in nigral neurons that were considered to be Marinesco bodies. Data obtained from the genome-wide linkage analysis revealed a maximal lod score of 3.46 at \( \theta = 0.00 \) for marker D20S199. This new SCA locus, on chromosome region 20p13-p12.3, was designated SCA23 after approval by the HUGO Nomenclature Committee. Currently, candidate genes are being screened for mutations within the SCA23 interval. In addition to the recently identified SCA14, SCA19 and FGF14 families, SCA23 is yet another novel SCA locus in the Dutch ADCA population, which further defines the genetic heterogeneity of ADCA families in the Netherlands.

Keywords: autosomal dominant cerebellar ataxia; neurodegenerative disorder; polyglutamine; human genetics; linkage analysis

Abbreviations: ADCA = autosomal dominant cerebellar ataxia; FGF14 = fibroblast growth factor 14; lod = logarithm of odds; SCA = spinocerebellar ataxia


Introduction
The autosomal dominant cerebellar ataxias (ADCAs) are a group of seriously invalidating disorders characterized by gait and limb ataxia, disturbances of speech and oculomotor control, in combination with variable other clinical features and usually with an adult age at onset (Harding, 1983). Harding’s classification of ADCAs into type I–III, based on the differential clinical features, is gradually being substituted by a classification based on molecular-genetic characteristics.

Since 1993, 11 spinocerebellar ataxia (SCA) genes have been cloned (SCA 1–3, 6–8, 10, 12, 14, 17 and fibroblast growth factor-14 (FGF14)) and an additional 12 SCA loci (SCA 4, 5, 11, 13, 15, 16, 18–21, 24 and 25) have been identified (HUGO Nomenclature Committee: http://www.gene.ucl.ac.uk/cgi-bin/nomenclature/searchgenes.pl) (Orr et al., 1993; Kawaguchi et al., 1994; Ranum et al., 1994; David et al., 1996; Flanigan et al., 1996; Imbert et al., 1996; Pulst et al., 1996; Sanpei et al., 1996; Zhuchenko et al., 1997; Holmes et al., 1999; Koide et al., 1999; Koob et al., 1999; Matsuura et al., 1999; Worth et al., 1999; Zu et al., 1999; Herman-Bert et al., 2000; Yamashita et al., 2000; Devos et al., 2001; Miyoshi et al., 2001; Nakamura et al., 2001; Swartz et al., 2002; Verbeek et al., 2002; Chen et al., 2003; Knight et al., 2003, 2004; Stevanin et al., 2004).

In SCA 1–3, 6, 7, and 17, the mutational mechanism is known to be a repeat expansion of coding CAG stretches leading to elongated polyglutamine tracts in the otherwise unrelated encoded proteins. However, in the SCA 8, 10, and 12 genes, the mutation involves a non-coding CTG, ATTCT and CAG repeat expansion, respectively (Holmes et al., 1999; Koob et al., 1999; Matsuura et al., 2000). Interestingly, the most recently identified mutations in the FGF14 gene and the SCA14 (PRKC6) gene turned out to be missense mutations.
mutations (Yue et al., 1997; Chen et al., 2003; van de Warrenburg et al., 2003; van Swieten et al., 2003; Yabe et al., 2003). Based on results of diagnostic testing of ADCA families, the estimated prevalence of ADCA in the Netherlands is about three per 100 000 individuals (van de Warrenburg et al., 2002). In ~30% of the Dutch ADCA families, no repeat expansion is identified in the SCA 1–3, 6, and 7 genes. So far, the SCA 10, 12 or 17 repeat expansions have not been reported in the Netherlands and the contribution of FGF14 mutations remains to be established. In addition, the contribution of the SCA14 mutations is currently being explored in our laboratory. So far, the SCA14 mutations seem to be restricted to the Cys2 region of the C1 domain, indicating a particular role for this part of the gene or the mutations that were identified. Still, we hypothesize that yet unidentified SCA genes are present in Dutch ADCA families.

Here, we present a Dutch ADCA family, clinically characterized by a late-onset (>40 years), slowly progressive, isolated SCA. Linkage analysis localized the disease gene to chromosome region 20p13-p12.3, and this locus was designated SCA23 (approved by the HUGO Nomenclature Committee). The identification of SCA23 further adds to the genetic heterogeneity of Dutch ADCA families.

Methods

The patients

The pedigree of the three-generation family that participated in this study is shown in Fig. 1. In order to maintain confidentiality, some individuals are depicted with the symbol sex unknown. All participating family members signed an informed consent. The study was approved by the University Medical Center Utrecht (Utrecht) Medical Ethical Committee. DNA samples were available from nine affected individuals and five presumptive unaffected relatives. Five of the affected family members were subjected to a thorough neurological examination. One asymptomatic carrier was detected.

Neuropathology and immunohistochemistry

The brain of subject II:11, who died in 1996 at the age of 80 years, was available for neuropathological examination and immunohistochemical studies. After formalin fixation and external neuropathological examination, the brain and spinal cord were examined at the cut surface, and multiple samples were taken and embedded in paraffin for histology. The following tinctorial stainings were performed on 4 mm histological sections of these samples: haematoxylin and eosin (H&E), Bodian silver, and a combined luxol fast blue (LFB) and H&E (LFB–H&E) staining. In addition, on sections of relevant areas (brain stem, spinal cord, cerebellum, hippocampus)

Fig. 1 Pedigree of the SCA23 family. Haplotype analysis is shown for 19 chromosome 20 markers. To maintain confidentiality, some individuals are depicted with the symbol sex unknown. The disease haplotype is boxed. Open figures = unaffected; closed figures = affected; dotted figures = asymptomatic carrier; square = male; circle = female; diamond = unknown sex; f = deceased.
immunohistochemical stainings were performed for ubiquitin (DAKO Cytomation, Heverlee, Belgium), tau (Innogenetics, Gent, Belgium), β-amyloid (DAKO Cytomation), α-synuclein (Neomarkers/Labvision, Fremont CA, USA), 1C2 (Chemicon International, Temecula, CA, USA), and ataxin-3 (Paulson et al., 1997).

**Mutation analysis of known SCA genes**

High molecular weight genomic DNA was isolated from peripheral blood leukocytes using routine salting-out procedures. Direct mutational analysis of trinucleotide repeat expansions of the SCA 1–3, 6–8, 12 and 17 genes was performed, but no repeat expansions were observed (data not shown). The other SCA loci (SCA 4–6, 10, 11, 13, 14, 16 and 19) were excluded by two-point linkage analysis (lod score < −2.0). The polymorphic markers used were selected from the Marshfield database: http://research.marshfieldclinic.org/genetics/Map_Markers/maps/IndexMapFrames.html.

**Genome-wide genotyping analysis**

After excluding the known SCA loci as candidates, a genome-wide scan was performed. The screening set consisted of 350 polymorphic markers, covering the whole genome. The average spacing between two adjacent markers was 10–15 cM. The protocol used to amplify the polymorphic markers was as described previously (Verbeek et al., 2002). Multiplex PCR products with HEX and FAM or HEX and TET labels were pooled. Finally, 1 ml of these pools were mixed with 4 ml HiDi (highly deionized formamide) including the internal lane standard ROX (Applied Biosystems, Foster City, CA, USA), and run on an automated high-throughput capillary electrophoresis ABI3700 machine (Applied Biosystems). Subsequently, fragment analysis and genotyping were performed using Genescan (v3.5 NT) and Genotyper (v2.1) software (Applied Biosystems). Two raters scored all genotypes independently.

**Linkage analysis**

Two-point lod (logarithm of odds) scores were calculated for each marker with the program MLINK (Lathrop and Lalouel, 1984), a multi-point analysis was performed to confirm the size of the candidate region. With the program LINKMAP of the LINKAGE (v5.2) package (Lathrop and Lalouel, 1984), a multi-point analysis was performed to confirm the size of the candidate region.

**Results**

**Clinical characteristics**

In the five family members examined, the age at onset ranged from 43 to 56 years (mean 50.4 ± 4.9 years) and disease duration varied from 1 to 23 years (mean 10.2 ± 8.4 years) (Table 1). The presence of clinical anticipation could not be studied because we were only able to examine affected subjects from the second generation. The age at onset of individual II:11, of whom blood and brain tissue was preserved, could not be extracted accurately from clinical records. Gait difficulties were the presenting feature in three subjects, while cycling difficulties and a simultaneous deterioration of gait and speech were the presenting signs in two others. After onset of disease, all displayed a slowly progressive, isolated SCA. In addition to gait and/or limb ataxia, which were present in all subjects, the neurological examination revealed dysarthria in three, slowing of both saccades and ocular dysmetria in three, decreased vibration sense below the knees in three, hyperreflexia in four, and Babinski’s sign in two affected subjects. Clinical severity grossly correlated with the duration of the disease; subject III:4, with a disease duration of 23 years, was wheelchair-bound outdoors. Cognitive deterioration or mental retardation, epilepsy, extrapyramidal features, signs of peripheral nerve involvement or sphincter abnormalities were not present. Neurophysiological studies were not conducted. An MRI-scan of the brain in subject III:4 at the age of 60 years showed severe cerebellar atrophy, normal brain stem structures and basal ganglia, no cerebral cortical atrophy, and multiple small subcortical white matter lesions in the cerebral hemispheres that resembled vascular disease.

**Neuropathology**

The brain weight was 930 g (normal for age = 1100–1400 g). Macroscopically, the cerebrum, cerebellum, brain stem and

<table>
<thead>
<tr>
<th>Table 1 Clinical characteristics of affected family members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>III:6</td>
</tr>
<tr>
<td>III:1</td>
</tr>
<tr>
<td>III:2</td>
</tr>
<tr>
<td>III:4</td>
</tr>
<tr>
<td>III:12</td>
</tr>
</tbody>
</table>

M = male; F = female; G = gait difficulties; C = cycling difficulties; S = speech difficulties; – = absent; ± = subtle; + = present or mild; ++ = moderate; +++ = severe; ↑ = increased; N = normal.
spinal cord showed generalized, moderate to severe atrophy. The atrophy was most pronounced in the frontotemporal region of the cerebrum, the vermis of the cerebellum, the basis pontis and the spinal cord. On the cut surface, marked dilatation of the cerebral ventricles was found with moderate, generalized atrophy of the central nuclei. The substantia nigra and locus ceruleus showed normal pigmentation.

Microscopically, pronounced neuronal loss was present in the Purkinje cell layer, especially in the vermis (Fig. 2A and B) and in dentate nuclei and inferior olives, accompanied by variable gliosis and myelin loss in the surrounding white matter. In the basis pontis, both the longitudinal and transverse white matter tracts were well myelinated, but the latter (i.e. cerebellopontine) tracts were relatively small.

No neuronal loss was observed within the pontine nuclei. The substantia nigra and locus ceruleus contained an ample number of pigmented neurons with sparse loose neuromelanin pigment and an occasional Lewy body in the substantia nigra. In the spinal cord, especially in the posterior and lateral columns moderate, dispersed loss of (staining for) myelin was found without inflammatory infiltrate or gliosis; there was no clear loss of motoneurons.

On thorough microscopic examination, only a few neurons in the substantia nigra contained striking intranuclear inclusions (Fig. 2C). These inclusions were round, 2–5 mm in diameter, strongly ubiquitin positive, but negative to the other immunohistochemical stainings (including 1C2 and ataxin-3) and therefore interpreted as Marinesco bodies. No other ubiquitin positive inclusions were found. In the

Fig. 2 Neuropathological findings. The cerebellar folia, especially of the rostral vermis (A,B), show severe atrophy with (sub)total loss of myelin in some parts (lighter staining, loosely textured area of white matter, indicated by arrowhead in A) and relative preservation of myelin in other parts of the white matter (darker staining for myelin in more compact area, indicated by arrow in A). Panel (B) represents a higher magnification of the area indicated by the rectangle in (A); it illustrates severe Purkinje cell loss, accompanied by Bergmann gliosis in the affected cerebellar cortex (arrows). Occasional neurons in the substantia nigra contain up to four round, intranuclear inclusions in (arrowheads in C, maximum diameter = 5 mm). These are strongly ubiquitin positive, but negative in the 1C2 and ataxin-3 staining and were therefore interpreted as Marinesco bodies. No pathological neuronal intranuclear inclusions were encountered in the CNS of this patient. (A,B) Luxol fast blue and haematoxylin and eosin staining. (C) Ubiquitin staining. Original magnification ×12.5 (A), ×100 (B) and ×400 (C).

α-synuclein staining, no cortical Lewy bodies were found. In the Bodian silver staining and in the immunohistochemical stainings for tau and β-amyloid, other ‘neurodegenerative depositions’ were generally scarce (neurofibrillary tangles, neuritic plaques) or absent (amyloid angiopathy, Pick bodies, oligodendrogial inclusions). In the tau-staining, some microand astroglial cells in and around central nuclei, dentate nuclei and substantia nigra were positive.

Vascular damage was present in the form of moderate to severe atherosclerosis of the circle of Willis and its major branches, with large recent ischemic necrotic areas in the left insular region (maximum 8 cm; territory of the left medial cerebral artery) and left occipital lobe (maximum 5 cm; territory of left posterior cerebral artery), and dispersed old ischemic necrotic lesions (cerebral white matter, hypothalamus, cerebellar cortex and white matter, basis pontis; maximum 1 cm). General autopsy revealed severe cachexia, emphysema, contractures of especially the lower limbs, and severe atherosclerosis of the large and middle-sized arteries with dispersed old infarcts in kidneys and spleen, myocardial hypertrophy and atheromatous plaques in the pulmonary artery (the latter indicating pulmonary hypertension).

**Linkage analysis**

The SCA loci were excluded in the initial analysis with two-point lod scores (data not shown). Next, a genome-wide screen was performed and only two genomic regions showed two-point lod scores of >1.0, including regions on
chromosomes 20 and 22. In addition, analysis of our data might be hampered by the presence of possible asymptomatic mutation carriers, an affected-only strategy was performed. This resulted in a maximal lod score ($Z_{\text{max}}$) of 3.46 at $\theta = 0.00$ for marker D20S199 (Table 2). The order and distance between the markers are based on the Marshfield database from April 2002 (http://research.marshfieldclinic.org/genetics/).

**Haplotype and multi-point linkage analysis**

Haplotypes were constructed by minimizing the number of possible recombination events (Fig. 1). The candidate interval directly starts from the tip of the short arm of chromosome 20, because no recombination events were detected with the most proximal marker D20S1155. A recombination event was observed in affected individual III:5 with marker D20S194 located at 18.2 cM, which determined the lower boundary of the interval. Multi-point linkage analysis (Fig. 3) based on the affected-only strategy was performed and resulted in a $Z_{\text{max}}$ of 3.56. Due to computer restraints, the multi-point analysis was calculated with three markers at the same time. The overlapping parts of the interval showed identical values, indicating that the analysis was performed correctly. The 95% candidate interval (maximum lod = $Z_{\text{max}}$) from the multi-point analysis is flanked by marker D20S1155 and marker D20S835, and spans around 15 cM.

**Candidate gene analysis**

The SCA23 interval is located between the tip of the short arm of chromosome 20 and D20S194, and is $\sim$18.2 cM in size, corresponding to $\sim$6.1 Mb, and contains around 100 genes. Our first attempt focused on candidate genes that contain coding triplet repeats. This resulted in the identification of two coding (CTG)$_5$ stretches in the GFR receptor $\alpha$-4 (Gfra4) gene and the Attractin with dipeptidylpeptidase IV activity (ATRN) gene.

Only one coding CAG repeat was identified; this was located in the ubiquitin-conjugating enzyme 7 interacting protein 3 gene. Four other non-coding intronic CAG repeats were located within the boundaries of the genes including $\beta$-neoeendorphin-dynorphin precursor ($PDYN$; (CTG)$_n$), KIAA1442 protein ($Q9P2A6$; (CTG)$_n$), ring finger protein 24 ($RNF24$; (CTG)$_n$), FK506 binding protein peptidyl prolyl cis trans isomerase ($FKBP1A$; (CTG)$_n$) and signal-regulatory protein $\beta$-1 precursor ($SIRP-\beta$-1; (CTG)$_n$). Four other CAG and CTG repeats with a maximal length of five repeats were identified, but it remained unclear whether these repeats are coding or non-coding sequences. However, no repeat expansions for any of these genes were observed (data not shown).

Secondly, only three other genes were selected for missense mutation screening including neuronal cell death inducible kinase ($SKIP3$), major prion protein precursor ($PRNP$) and the prion gene complex downstream ($PRND$). In addition, over-expression of Doppel ($Dpl$), the paralog of the mammalian prion protein ($PrP$), is correlated with ataxia and death of cerebellar neurons in mice. All three genes were excluded as candidates based on our sequence data results.

**Table 2 Two-point lod scores between the disease locus and 11 chromosome 20 Markers**

<table>
<thead>
<tr>
<th>Markers</th>
<th>Lod score at recombination rate (θ)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.00</td>
</tr>
<tr>
<td>D20S1155</td>
<td>2.22</td>
</tr>
<tr>
<td>D20S103</td>
<td>1.48</td>
</tr>
<tr>
<td>D20S117</td>
<td>2.49</td>
</tr>
<tr>
<td>D20S199</td>
<td>3.46</td>
</tr>
<tr>
<td>D20S473</td>
<td>0.39</td>
</tr>
<tr>
<td>D20S867</td>
<td>1.66</td>
</tr>
<tr>
<td>D20S835</td>
<td>2.02</td>
</tr>
<tr>
<td>D20S194</td>
<td>-4.57</td>
</tr>
<tr>
<td>D20S907</td>
<td>-0.08</td>
</tr>
<tr>
<td>D20S901</td>
<td>1.27</td>
</tr>
<tr>
<td>D20S160</td>
<td>-6.50</td>
</tr>
</tbody>
</table>
Discussion
The genome scan in this three-generation Dutch ADCA family resulted in the identification of a novel SCA locus, designated SCA23, on chromosome region 20p13-12.3. Clinically, the affected family members displayed a late-onset (>40 years), slowly progressive, isolated SCA. Features mainly included gait and limb ataxia, disturbance of oculomotor control, dysarthria and hyperreflexia. As distinctive extracerebellar disease features are absent, the SCA23 phenotype is clinically indistinguishable from other SCA subtypes; relatively pure cerebellar syndromes have also been described in SCA5, SCA6, SCA11, SCA14, SCA15, SCA16 and SCA22 (Schols et al., 2004). Genome-wide linkage analysis revealed a maximal two-point lod score ($Z_{\text{max}}$) of 3.46 at $\theta = 0.00$ with marker D20S199. The SCA23 interval is located between the tip of the short arm of chromosome 20 and D20S194, and is ~18.2 cM in size, corresponding to ~6.1 Mb, and containing ~100 genes.

Our candidate genes analysis was unable to identify the SCA23 disease-causing mutation. We focused on candidate genes that contain coding triplet repeats, since this is the most common mutation in the ADCAs worldwide. We also searched for missense mutations in genes that correlated with ataxia and death of cerebellar neurons in mice, considering the fact that the two most recently identified SCA mutations were point mutations.

The neuropathological findings in subject II:11 grossly correspond to previous observations in this group of disorders, although we did not observe the neuronal intranuclear inclusions typically encountered in polyQ-associated ADCAs (Robitaille et al., 1997; Schols et al., 2004) Some nigral neurons were found to contain ubiquitin-positive intranuclear inclusions, very much reminiscent of Marinesco bodies. In addition, Lewy bodies were occasionally present in nigral neurons. Substantia nigra involvement has been reported in SCA2 and SCA3 patients (Orozco et al., 1989; Durr et al., 1996). Unfortunately, it is not known whether subject II:11 displayed additional parkinsonian features. Marinesco bodies are non-specific ubiquinated intranuclear inclusions in nigral neurons observed in, for example, normal ageing and Alzheimer’s disease. Interestingly, wild-type ataxin-3, the mutated protein in SCA3, was recently found to be recruited to Marinesco bodies in both non-human primates and in myotonic dystrophy patients (Kettner et al., 2002; Kumada et al., 2002). In our case, we did not find the Marinesco bodies to be immunopositive for ataxin-3, but this may be due to the fact that different antibodies were used. How this finding of Marinesco bodies relates to the pathogenic processes involved in SCA23 and whether this also indicates failure of protein homeostasis mechanisms remains to be established (mainly by identifying the mutated gene product).

In conclusion, the SCA23 locus is a novel locus identified in the Dutch ADCA population. The candidate interval is located on chromosome region 20p13-12.3 and is ~18.2 cM. In an attempt to refine the size of the candidate interval, we are currently trying to identify additional ADCA families that also link to the SCA23 locus.

Acknowledgements
The authors wish to thank all the family members for participating in this study, Jackie Senior for improving the manuscript, and Lude Franke for designing the repeat finder program. We also wish to thank Rob de Vos (Department of Pathology, Medisch Spectrum Twente, the Netherlands) for his help with the immunohistochemical stainings and for fruitful discussions. This work was supported by grant MAR00-107 from the Prinses Beatrix Fonds, the Netherlands, and research grant (97252) from the Faculty of Medicine, University of Nijmegen, the Netherlands.

References


